ESTRO 2023 - Abstract Book

S1004

Digital Posters

ESTRO 2023

1 Kuopio University Hospital, Cancer Centre, Kuopio, Finland; 2 University of Eastern Finland, Faculty of Health Sciences, Kuopio, Finland; 3 University of Eastern Finland, Department of Applied Physics, Kuopio, Finland Purpose or Objective The purpose of this study was to report the clinical outcomes and toxicity after VMAT and 3D-CRT delivery techniques as adjuvant treatment after breast-conserving surgery. Materials and Methods We retrospectively analyzed 239 left or right sided breast cancer patient divided in two cohorts: patients treated in 2011 with 3D-CRT technique (n=111) and patients treated in 2018 with VMAT technique (n=128) [1]. In addition, in 2018 most (82%) of the left sided patients were treated in DIBH. The patient characteristics are presented in Table 1. Of the 2011 group 79.3% were treated with conventional fractionation (25x2Gy ad 50Gy) and the rest with hypofractionation (15x2.67Gy ad 40.05Gy) as in the 2018 group 24% were treated with conventional fractionation and 76% with hypofractionation. Besides the whole breast, also the axillary lymph node area was treated in 39% and 28% of the 2011 and 2018 patients, respectively. Clinical information, such as patients' skin toxicity, lymphedema, and cardiac toxicity, was collected from the patient medical records and acute and late ( ≥ 6 months) toxicity and cosmetic data were analyzed. All the cardiac complications were recorded in 2021, thus the 2011 patient group had longer follow-up than the 2018 group. The severities of all the symptoms were assessed based on the record of the attending physician. Table 1: Characteristics of the patients treated in 2011 and 2018.

Results Of the patients treated in 2011 95.5% had some acute toxicity, redness of the skin being the most common (85%) as of the patients treated in 2018 the corresponding figures were 82.9% and 75%. Dermatitis was observed in 21.6% and 6.2% for the patient groups of 2011 and 2018 and symptoms of hypoesthesia were recorded for 14.4% and 21.7% of the 2011 and 2018 patient groups, respectively. The recorded late complications are presented in Table 2. Overall, the late cosmetic outcomes were better with the patients treated with the VMAT technique in 2018. The recorded lymphedema between the groups of 2011 and 2018 were 12% and 15%, respectively. Locoregional relapse and/or distant metastasis was observed in 3.6% and 1.6% or 13.5% and 3.1% of the patients treated in 2011 and 2018, respectively. Table 2: Recorded symptoms at one year after the start of RT of the patients treated in 2011 and 2018. The patient groups are sorted by RT fractionation (hypofractionation and conventional fractionation).

Conclusion